259 related articles for article (PubMed ID: 36091147)
1. CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials.
Xu H; Wang Y; Han Y; Wu Y; Wang J; Xu B
Front Oncol; 2022; 12():956464. PubMed ID: 36091147
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis.
Han Y; Wang J; Wang Z; Xu B
Curr Probl Cancer; 2020 Dec; 44(6):100606. PubMed ID: 32446638
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors as second-line treatment in postmenopausal patients with hormone receptor-positive, HER-2-negative metastatic breast cancer: a network meta-analysis.
Leung JH; Leung HWC; Wang SY; Huang SS; Chan ALF
Expert Opin Drug Saf; 2021 Aug; 20(8):949-957. PubMed ID: 34047239
[TBL] [Abstract][Full Text] [Related]
4. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
[TBL] [Abstract][Full Text] [Related]
5. CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis.
Ji D; Luo Y; Wang J; Chen S; Lan B; Ma F; Xu B; Fan Y
BMC Cancer; 2023 Aug; 23(1):805. PubMed ID: 37644396
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, advanced breast cancer: a systematic review and meta-analysis.
Dai Q; Wang Y; Liao M; Chen H
Ann Palliat Med; 2022 Dec; 11(12):3727-3742. PubMed ID: 36635998
[TBL] [Abstract][Full Text] [Related]
8. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
9. CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials.
Messina C; Cattrini C; Buzzatti G; Cerbone L; Zanardi E; Messina M; Boccardo F
Breast Cancer Res Treat; 2018 Nov; 172(1):9-21. PubMed ID: 30054831
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of PI3K/Akt/mTOR inhibitors combined with trastuzumab therapy for HER2-positive breast cancer: a meta-analysis.
Peng DS; Huang BQ; Ning HT; Zhu XZ
Eur Rev Med Pharmacol Sci; 2022 Oct; 26(20):7667-7678. PubMed ID: 36314338
[TBL] [Abstract][Full Text] [Related]
11. Overall survival and progression-free survival with cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in breast cancer: an updated meta-analysis of randomized controlled trials.
Tian Q; Gao H; Zhou Y; Yang J
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7252-7267. PubMed ID: 34919224
[TBL] [Abstract][Full Text] [Related]
12. The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis.
Mastrantoni L; Orlandi A; Palazzo A; Garufi G; Fabi A; Daniele G; Giannarelli D; Tortora G; Bria E
EClinicalMedicine; 2023 Feb; 56():101824. PubMed ID: 36713467
[TBL] [Abstract][Full Text] [Related]
13. Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape.
Beith J; Burslem K; Bell R; Woodward N; McCarthy N; De Boer R; Loi S; Redfern A
Asia Pac J Clin Oncol; 2016 Mar; 12 Suppl 1():3-18. PubMed ID: 27001208
[TBL] [Abstract][Full Text] [Related]
14. Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.
Martel S; Bruzzone M; Ceppi M; Maurer C; Ponde NF; Ferreira AR; Viglietti G; Del Mastro L; Prady C; de Azambuja E; Lambertini M
Cancer Treat Rev; 2018 Jan; 62():123-132. PubMed ID: 29108713
[TBL] [Abstract][Full Text] [Related]
15. Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: a systematic review and network meta-analysis.
Wang Y; Xu H; Han Y; Wu Y; Sa Q; Wang J
ESMO Open; 2023 Jun; 8(3):101216. PubMed ID: 37084609
[TBL] [Abstract][Full Text] [Related]
16. Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2- metastatic breast cancer.
Pan M; Lin Y; Liu Y; Xu R; Yang J
Eur J Clin Pharmacol; 2024 Jun; ():. PubMed ID: 38900307
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
[TBL] [Abstract][Full Text] [Related]
18. CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis.
Agostinetto E; Vian L; Caparica R; Bruzzone M; Ceppi M; Lambertini M; Pondé N; de Azambuja E
ESMO Open; 2021 Apr; 6(2):100091. PubMed ID: 33743330
[TBL] [Abstract][Full Text] [Related]
19. Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
Piezzo M; Chiodini P; Riemma M; Cocco S; Caputo R; Cianniello D; Di Gioia G; Di Lauro V; Rella FD; Fusco G; Iodice G; Nuzzo F; Pacilio C; Pensabene M; De Laurentiis M
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32899139
[TBL] [Abstract][Full Text] [Related]
20. Systematic review and meta-analysis of post-progression outcomes in ER+/HER2- metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials.
Munzone E; Pagan E; Bagnardi V; Montagna E; Cancello G; Dellapasqua S; Iorfida M; Mazza M; Colleoni M
ESMO Open; 2021 Dec; 6(6):100332. PubMed ID: 34864350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
